Skip to content
National Cancer Institute
U.S. National Institutes of Health
| www.cancer.gov
In English |
En español
Search
NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
Clinical Trials Search Results
Quick Links
Director's Corner
Dictionary of Cancer Terms
NCI Drug Dictionary
Funding Opportunities
NCI Publications
Advisory Boards and Groups
Science Serving People
Español
Questions about cancer?
1-800-4-CANCER
LiveHelp® online chat
NCI Highlights
High Dose Chemotherapy Prolongs Survival for Leukemia
Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E
Past Highlights
Results:
1 -10 of 14
Show
10
25
50
100
200
results per page
View Search Criteria
|
Help With Results
Sort By:
Phase of Trial
Title
Type of Trial
Status of Trial
Age Range
Sponsor of Trial
Protocol IDs
Version:
Health Professional
Patient
Format:
Short
------
Short
Medium
Long
Custom
1.
PROMPT - Palifermin in Reduction of Oral Mucositis in PBSC Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase IV
Supportive care, Treatment
Completed
18 and over
Pharmaceutical / Industry
20050100
NCT00352703
2.
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III, Phase II
Supportive care, Treatment
Closed
18 and over
Pharmaceutical / Industry
20040122
NCT00393822
Last Modified:
2/3/2005
 
First Published:
7/1/2001
3.
Phase III Randomized Study of Recombinant Human Keratinocyte Growth Factor in Reducing Therapy-Induced Oral Mucositis in Patients With Hematologic Malignancies Undergoing Total Body Irradiation and High-Dose Chemotherapy Followed By Autologous Peripheral Blood Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Closed
18 and over
NCI, Pharmaceutical / Industry
UCLA-0012064
AMGEN-KGF-20000162, FHCRC-1612.00, MSKCC-01065, NCI-G01-1961
4.
Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care
Closed
18 and over
Pharmaceutical / Industry
20020402
NCT00101582
5.
A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Advanced Head and Neck Cancer
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Closed
18 and over
Pharmaceutical / Industry
20040118
NCT00131638
Last Modified:
11/1/2008
 
First Published:
7/25/2006
6.
Phase III Randomized Study of Palifermin for Reducing Oral Mucositis in Patients With Locally Advanced Squamous Cell Carcinoma of the Oral Cavity, Oropharynx, Hypopharynx, or Larynx Undergoing Concurrent Radiotherapy and Chemotherapy
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase III
Supportive care, Treatment
Completed
18 and over
NCI
RTOG-0435
RTOG 0435, NCT00360971
Last Modified:
12/1/1999
 
First Published:
2/1/1998
7.
Phase I/II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients with Hodgkin's Disease and Non-Hodgkin's Lymphoma Undergoing High Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Supportive care, Treatment
Closed
16 and over
Pharmaceutical / Industry
MSKCC-97112
AMGEN-KGF-960189, NCI-G97-1368
Last Modified:
3/1/2000
 
First Published:
4/1/1998
8.
Phase I/II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients With Head and Neck Cancer Undergoing Chemoradiotherapy (Summary Last Modified 03/2000)
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II, Phase I
Treatment
Closed
Adult
NCI
RPCI-DS-97-33
AMGEN-KGF-970149-08, NCI-G98-1397
Last Modified:
6/1/2007
 
First Published:
11/1/1999
9.
Phase II Randomized Study of Recombinant Human Keratinocyte Growth Factor in Patients with Hematologic Malignancies Undergoing Total Body Irradiation and High Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Support
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Closed
18 to 65
NCI, Pharmaceutical / Industry
MSKCC-99029
AMGEN-KGF-980231-04, NCI-G99-1574, NCT00004061
Last Modified:
6/1/2007
 
First Published:
12/1/1999
10.
Phase II Randomized Study of Recombinant Human Keratinocyte Growth Factor for Oral Mucositis in Patients With Hematologic Malignancies Undergoing Radiotherapy and High Dose Chemotherapy Prior to Autologous Peripheral Blood Stem Cell Transplantation
Phase
Type
Status
Age
Sponsor
Protocol IDs
Phase II
Supportive care, Treatment
Completed
12 to 65
NCI, Pharmaceutical / Industry
UCLA-9812041
AMGEN-KGF-980231-03, NCI-G99-1609, NCT00004132
Select All on One Page
1
2
Next >
NCI Home
|
Images Version
|
Contact Us
|
Policies
|
Accessibility
|
Viewing Files
|
FOIA
|
Site Help
|
Site Map
A Service of the National Cancer Institute